Basilea Pharmaceutica AG

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public

Established: 2000-01-01

Employees: 147

Market Cap: $676.7M

Website: http://www.basilea.com

Clinical Trials

A Study Evaluating the Pharmacokinetics of Ceftobiprole When Taken by Obese Patients

Phase 1

Completed

Conditions: Obesity
Staphylococcal Skin Infections
Streptococcal Infections

Interventions: Drug: Ceftobiprole

First Posted Date: 2009-12-04

Last Posted Date: 2012-08-28

Lead Sponsor: Basilea Pharmaceutica

Target Recruit Count: 25

Registration Number: NCT01026558

Effect of Ceftobiprole on Human Intestinal Microflora

Phase 1

Completed

Conditions: Antimicrobial Agent
Cephalosporins
Drug Resistance

Interventions: Drug: Ceftobiprole

First Posted Date: 2009-08-25

Last Posted Date: 2012-07-30

Lead Sponsor: Basilea Pharmaceutica

Target Recruit Count: 12

Registration Number: NCT00965042

Pharmacokinetic Study of the Penetration of Ceftobiprole in the Bone

Phase 1

Completed

Conditions: Total Hip Replacement Surgery

Interventions: Drug: Ceftobiprole

First Posted Date: 2008-10-13

Last Posted Date: 2012-07-30

Lead Sponsor: Basilea Pharmaceutica

Target Recruit Count: 22

Registration Number: NCT00771524

Open Label Pharmacokinetic in Adult Patients With Ventilator-Associated Pneumonia

Phase 1

Terminated

Conditions: Ventilator Associated Pneumonia

Interventions: Drug: Ceftobiprole

First Posted Date: 2008-10-13

Last Posted Date: 2012-07-30

Lead Sponsor: Basilea Pharmaceutica

Target Recruit Count: 1

Registration Number: NCT00771719

Open Label Study of Ceftobiprole to Evaluate Pharmacokinetics in Adults Hospitalized in the ICU

Phase 1

Completed

Conditions: ICU

Interventions: Drug: ceftobiprole q12h
Drug: ceftobiprole q8h

First Posted Date: 2008-10-10

Last Posted Date: 2012-07-30

Lead Sponsor: Basilea Pharmaceutica

Target Recruit Count: 33

Registration Number: NCT00770978

A Study of Ceftobiprole in Patients With Fever and Neutropenia.

Phase 3

Terminated

Conditions: Fever
Neutropenia
Gram-positive Bacterial Infections
Pseudomonas Infection

Interventions: Drug: Ceftobiprole Medocaril
Drug: Cefepime with or without vancomycin

First Posted Date: 2007-09-14

Last Posted Date: 2012-08-01

Lead Sponsor: Basilea Pharmaceutica

Target Recruit Count: 2

Registration Number: NCT00529282

Alitretinoin in the Treatment of Chronic Hand Eczema

Phase 3

Completed

Conditions: Eczema

First Posted Date: 2007-08-23

Last Posted Date: 2023-05-10

Lead Sponsor: Basilea Pharmaceutica

Target Recruit Count: 150

Registration Number: NCT00519675

Ceftobiprole in the Treatment of Hospitalized Patients With Staphylococcus Aureus Bacteremia

Phase 2

Withdrawn

Conditions: Bacteremia

First Posted Date: 2007-07-23

Last Posted Date: 2013-02-20

Lead Sponsor: Basilea Pharmaceutica

Registration Number: NCT00505258

Safety, Efficacy and Pharmacokinetics of an Antifungal in Patients Undergoing Chemotherapy

Phase 2

Completed

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Isavuconazole

First Posted Date: 2006-12-19

Last Posted Date: 2023-05-10

Lead Sponsor: Basilea Pharmaceutica

Target Recruit Count: 18

Registration Number: NCT00413439

Locations: 🇩🇪
University Cologne, Cologne, Germany

Ceftobiprole in the Treatment of Patients With Community-Acquired Pneumonia

Phase 3

Completed

Conditions: Pneumonia

Interventions: Drug: Ceftriaxone with or without Linezolid
Drug: Ceftobiprole medocaril

First Posted Date: 2006-05-16

Last Posted Date: 2012-08-02

Lead Sponsor: Basilea Pharmaceutica

Target Recruit Count: 638

Registration Number: NCT00326287

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy